EssilorLuxottica to Acquire Optegra, Expanding Presence in European Ophthalmology Market

EssilorLuxottica has entered into an agreement with MidEuropa to acquire Optegra, a European ophthalmology provider operating in the UK, Czech Republic, Poland, Slovakia, and the Netherlands. The acquisition is part of EssilorLuxottica’s broader med-tech strategy and is expected to close in late 2025, pending regulatory approvals and customary closing conditions.

Optegra's Network and Clinical Services

Optegra, operating under the Optegra, Lexum, and Iris brands, manages a network of more than 70 eye hospitals and diagnostic facilities. The group offers a range of ophthalmic treatments, including:

       • Cataract surgery

       • Treatment for glaucoma and age-related macular degeneration (AMD)

       • Refractive lens exchange

       • Laser eye surgery

Its services are provided to both publicly reimbursed and private-pay patients. The organization also integrates AI technologies in pre- and post-operative care workflows.

Strategic Context for EssilorLuxottica

This acquisition supports EssilorLuxottica’s strategy to expand into clinical eyecare, complementing its existing portfolio of products and services, which includes:

       • Eyewear and lenses

       • AI-driven diagnostic technologies

       • Medical instruments

       • Wearable and digital health solutions

“With the acquisition of Optegra, we are stepping into a new frontier—one where comprehensive eyecare, advanced diagnostics, therapeutic interventions, and surgical treatments come together in one seamless platform,” said Francesco Milleri, Chairman and Chief Executive Officer of EssilorLuxottica, and Paul du Saillant, Deputy CEO.

“Optegra and its experienced doctors will bring new medical capabilities to our Group, enabling us to address patients’ needs with the most advanced vision care technologies and treatments in one trusted system that will anchor our med-tech aspirations.”